

10-06-05

F.W.
Express Mail No.: EV 456 920 725 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Collins *et al.*

Confirmation No.: 4775

Serial No.: 10/654,112

Art Unit: 1626

Filed: September 2, 2003

Examiner: Kantamneni, Shobha

For: MODULATION OF CCR4 FUNCTION

Attorney Docket. No. 11134-065-999

(formerly 018781-008610US)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of References A11-A21 are submitted herewith. References A01-A09 are U.S. patents and A10 is a U.S. published application. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Serial No. 10/654,112

Page 2

Pursuant to 37 C.F.R. §1.97(b), since this information disclosure statement is being filed before the mailing of the first Office action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day deposit account no. 50-3013 (referencing 893053-999065); a duplicate of this sheet is enclosed.

Respectfully submitted,

Date: October 4, 2005


42,983


Rahul Pathak

(Reg. No.)

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 11134-065-999	APPLICATION NO 10/654,112
		APPLICANT Collins <i>et al.</i>	
		FILING DATE September 2, 2003	GROUP 1626



U.S. PATENT DOCUMENTS

EXAMINER	ART UNIT	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		A01 3,201,409	8/17/65	Spivack <i>et al.</i>			
		A02 3,228,888	1/11/66	Spivack <i>et al.</i>			
		A03 5,919,776	7/6/99	Hagmann <i>et al.</i>			
		A04 6,207,665	3/27/01	Weier <i>et al.</i>			
		A05 6,426,360	7/30/02	Weier <i>et al.</i>			
		A06 6,436,967	8/20/02	Talley <i>et al.</i>			
		A07 6,496,161	12/24/02	Caldwell <i>et al.</i>			
		A08 6,706,767	3/16/04	Saxena <i>et al.</i>			
		A09 6,784,195	8/31/04	Hale <i>et al.</i>			
		A10 2002-0173524 A1	11/21/02	Collins <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	A11 ✓	International Search Report for PCT/US02/16395	10/25/02	PCT					
	A12 ✓	Supplementary Partial European Search Report for EP Appl'n EP 01 98 1850	3/3/05	EP					
	A13	EP 0 310 370	4/5/89	EP					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A14	Baggiolini <i>et al.</i> , 1998, "Chemokines and Leukocyte Traffic," <i>Nature</i> 392:565-568.
A15	Baggiolini <i>et al.</i> , 1997, "Blocking Chemokines Receptors," <i>J. Exp. Med.</i> 186:1189-1191.
A16	Imai <i>et al.</i> , 1997, "Macrophage-Derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4," <i>J. Biol. Chem.</i> 273:1764-1768.
A17	Imai <i>et al.</i> , 1998, "The T-Cell-Directed CC Chemokine TARC is a Highly Specific Biological Ligand for CC Chemokine Receptor 4," <i>J. Biol. Chem.</i> 272:15036-15042.
A18	Kita <i>et al.</i> , 1996, "Chemokines Active on Eosinophils: Potential Roles in Allergic Inflammation," <i>J. Exp. Med.</i> 183:2421-2426.
A19	Muller <i>et al.</i> , 2004, "Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis," <i>Curr. Drug Targets Inflamm. Allergy</i> 3(3):279-290.
A20	National Institutes of Health, 2005, Web page (http://www.csr.nih.gov/review/cvsirg.htm) referring to atherosclerosis and Inflammation of the Cardiovascular System [AICS] pgs. 1-5.
A21	Sun <i>et al.</i> , 2004, "Cytokine-Induced Enhancement of Autoimmune Inflammation in the Brain and Spinal Cord: Implications for Multiple Sclerosis," <i>Neuropathol. Appl. Neurobiol.</i> 30(4):374-384.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	